Citi eyes China brokerage unit licence as soon as this month, sources say
Citigroup expects regulatory approval for its wholly-owned China brokerage business as soon as this month, according to sources. The bank plans to double staff to around 100 by year-end, competing with JPMorgan, Goldman Sachs, and Morgan Stanley in China's securities market. Citi aims to offer A-share brokerage, underwriting, research, and principal trading services, targeting tech, healthcare, and consumer sectors.
How this was made

The 30-second read
Why it matters
The anticipated licence could allow Citi to capture a share of the growing on‑shore securities market, enhancing its China franchise.
Market read
First report of potential regulatory approval for Citi's China brokerage unit, indicating a material expansion opportunity.
What to watch
Potential headcount costs and integration challenges may offset revenue gains.
Background
Citi has been preparing for a China brokerage licence since 2021, hiring staff and planning A‑share services.
Ticker impact
Citi expects regulatory approval this month for its wholly‑owned China brokerage unit, a first‑time disclosure.
Short‑term upside as investors price in new China franchise.
Approval is not guaranteed, but the announcement signals a material expansion opportunity.
Market effects
Adds competitive pressure on JPM, GS, MS in China on‑shore brokerage.
May increase foreign bank participation in Chinese securities markets.
Highlights ongoing liberalization of China's financial sector.
Counterpoint
Regulatory risk remains high; approval could be delayed, limiting near‑term upside.
Key entities
- CompanyCitigroup Inc.
U.S. bank seeking China brokerage licence.



